[go: up one dir, main page]

GT201300252A - Alfa glucosidasa ácida modificada con procesamiento acelerado - Google Patents

Alfa glucosidasa ácida modificada con procesamiento acelerado

Info

Publication number
GT201300252A
GT201300252A GT201300252A GT201300252A GT201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A GT 201300252 A GT201300252 A GT 201300252A
Authority
GT
Guatemala
Prior art keywords
accelerated processing
modified acid
alfa
glucosidase modified
glucosidase
Prior art date
Application number
GT201300252A
Other languages
English (en)
Inventor
William M Canfield
Rodney J Moreland
Mariko Kudo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300252A publication Critical patent/GT201300252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PROPORCIONA UN POLIPÉPTIDO DE ALFA-GLUCOSIDASA ÁCIDA HUMANA MODIFICADA, QUE TIENE HIDROFOBICIDAD INCREMENTADA DE 70 KDA CERCA DEL EXTREMO N-TERMINAL, ASÍ COMO MÉTODOS PARA PRODUCIR Y USAR LA ALFA-GLUCOSIDASA ÁCIDA HUMANA MODIFICADA PARA TRATAR UNA GLUCOGENOSIS.
GT201300252A 2011-04-22 2013-10-18 Alfa glucosidasa ácida modificada con procesamiento acelerado GT201300252A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
GT201300252A true GT201300252A (es) 2015-02-09

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300252A GT201300252A (es) 2011-04-22 2013-10-18 Alfa glucosidasa ácida modificada con procesamiento acelerado

Country Status (24)

Country Link
US (1) US20140186326A1 (es)
EP (1) EP2699676A1 (es)
JP (2) JP2014513952A (es)
KR (1) KR20140037082A (es)
CN (1) CN103797115A (es)
AU (1) AU2012245280A1 (es)
BR (1) BR112013026976A2 (es)
CA (1) CA2833371A1 (es)
CL (1) CL2013003010A1 (es)
CO (1) CO6811810A2 (es)
CR (1) CR20130555A (es)
EC (1) ECSP13013036A (es)
GT (1) GT201300252A (es)
IL (1) IL228871A0 (es)
MA (1) MA35125B1 (es)
MX (1) MX2013012345A (es)
NI (1) NI201300110A (es)
PE (1) PE20140617A1 (es)
PH (1) PH12013502149A1 (es)
RU (1) RU2013151875A (es)
SG (2) SG194486A1 (es)
TN (1) TN2013000427A1 (es)
WO (1) WO2012145644A1 (es)
ZA (1) ZA201307696B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
KR102741048B1 (ko) 2014-09-30 2024-12-11 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
WO2017079729A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
KR20250017756A (ko) 2016-03-30 2025-02-04 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
MX2018011951A (es) * 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
IL299325B2 (en) 2016-09-12 2025-08-01 Inst Nat Sante Rech Med Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
HRP20230576T1 (hr) 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
KR20250140631A (ko) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 항-cd63 항체, 콘쥬게이트, 및 이의 용도
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
JP2023503046A (ja) * 2019-11-19 2023-01-26 アスクレピオス バイオファーマシューティカル， インコーポレイテッド ポンペ病およびリソソーム障害を処置するための肝臓特異的プロモーターを含む治療用アデノ随伴ウイルス

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
EP2147681A1 (en) 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
JP4990434B2 (ja) * 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
ES2395463T3 (es) 2001-07-16 2013-02-15 Genzyme Corporation Un inhibidor de N-acilesfingosina glucosiltransferasa
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
DK1639112T3 (en) 2003-06-24 2015-07-06 Genzyme Corp Hitherto UNKNOWN BETA-ACTIN AND RPS21 PROMOTORS AND USES THEREOF
EP1716232B9 (en) * 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
HUE060974T2 (hu) 2008-12-16 2023-04-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállítására
US8466340B2 (en) * 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
CL2013003010A1 (es) 2014-03-07
SG10201605874TA (en) 2016-09-29
JP2014513952A (ja) 2014-06-19
IL228871A0 (en) 2013-12-31
MX2013012345A (es) 2015-05-07
PE20140617A1 (es) 2014-05-28
EP2699676A1 (en) 2014-02-26
CN103797115A (zh) 2014-05-14
PH12013502149A1 (en) 2019-09-02
JP2017035091A (ja) 2017-02-16
NI201300110A (es) 2014-02-28
MA35125B1 (fr) 2014-05-02
CA2833371A1 (en) 2012-10-26
RU2013151875A (ru) 2015-05-27
AU2012245280A1 (en) 2013-11-07
SG194486A1 (en) 2013-12-30
US20140186326A1 (en) 2014-07-03
KR20140037082A (ko) 2014-03-26
TN2013000427A1 (en) 2015-03-30
CO6811810A2 (es) 2013-12-16
ZA201307696B (en) 2014-07-30
WO2012145644A1 (en) 2012-10-26
BR112013026976A2 (pt) 2019-09-24
ECSP13013036A (es) 2015-04-30
CR20130555A (es) 2013-12-09

Similar Documents

Publication Publication Date Title
GT201300252A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
MX2019009437A (es) Tratamiento de mielosupresion.
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
MX2015016406A (es) Formulacion de revestimiento para madera.
MX377149B (es) Microorganismo recombinante para la produccion mejorada de productos quimicos finos.
MX378313B (es) Produccion microbiana de dioles grasos.
CL2018000671A1 (es) Expresión de proteínas recombinantes en pupas de trichoplusia ni
BR112017025322A8 (pt) Processos integrados para recuperação de hidrolisato celulósico após hidrólise de polpa de celulose
BR112015030655A2 (pt) Variantes de xilanase e polinucleótidos que codificam as mesmas
MX2017011976A (es) Microorganismo recombinante para la produccion mejorada de quimicos finos.
EA201891226A1 (ru) Способ сокращения общего потребления электроэнергии при производстве наноцеллюлозы
UY34408A (es) Nuevos moduladores de trpv3
BR112015022266A2 (pt) processo e sistema eletroquímicos para a produção de glicose
BR112018010631A2 (pt) uso de oxigênio dissolvido para inibir a produção de ácido láctico durante a propagação de levedura e/ou hidrólise de biomassa de lignocelulose
BR112016029572A2 (pt) variantes de exoglucanases que possuem atividade melhorada e utilizações das mesmas
BR102012023867A2 (pt) Método de pré-tratamento para produzir açúcares solúveis em água a partir de material lignocelulósico
MX382334B (es) Métodos para producir glucoproteínas recombinantes con glucosilación modificada.
MX2017000785A (es) Proceso de acetilacion de la madera.
BR112012008017A2 (pt) 1,2,4-triazina, utilização de uma 1,2,4-triazina e processo de preparação de uma 1,2,4-triazina